
OMDA Stock Forecast & Price Target
OMDA Analyst Ratings
Bulls say
Omada Health Inc exhibits a promising growth trajectory, supported by a projected revenue increase of over 35% in FY25 and a strong move towards adjusted EBITDA breakeven. The company's margin expansion, driven by AI integration that enhances efficiency and member engagement, further strengthens its financial position, particularly as it capitalizes on its role as a companion solution for GLP-1 medication users. Additionally, the rise in enrollments due to targeted outreach, along with expanding partnerships with prominent pharmacy benefit managers such as Express Scripts and CVS Caremark, underscores Omada's potential to gain market share and deliver significant value amidst increasing corporate interest in GLP-1 treatments.
Bears say
Omada Health Inc has experienced a reduction in adjusted operating expenses as a percentage of revenue from FY’22 to FY’24, dropping from 121.1% to 80.5%, indicating improving operational efficiency. However, despite this progress, forecasts suggest that average revenue per user (ARPU) will remain relatively flat, raising concerns about revenue growth potential in subsequent years. Additionally, potential declines in demand for Omada’s GLP-1 CareTracks, linked to safety issues and evolving market dynamics, combined with the risk of deteriorating relationships with key partners, could significantly hinder the company's financial performance and long-term scalability.
This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.
OMDA Analyst Forecast & Price Prediction
Start investing in OMDA
Order type
Buy in
Order amount
Est. shares
0 shares